Systemic exposure to rosiglitazone is unaltered by food

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 53-56

  Freed, M I ^a,b   Allen, A ^b   Jorkasky, D K ^a   DiCicco, R A ^a,b  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bioavailability; PPAR agonist; Thiazolidinedione

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DIETARY FATS; FASTING; FOOD-DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033002651     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050592     Document Type: Article

References (21)

1. Consensus Panel (1996) Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 19 [Suppl 1]: S54-S61
2. American Diabetes Association (1997) Clinical practice recommendations 1997. Diabetes Care 20 [Suppl 1]: S1-S70
3. Anderson KE (1998) Influences of diet and nutrition on clinical pharmacokinetics. Clin Pharmacokinet 14: 325-346
4. Roland M, Tozer TN (1995) Absorption. In: Clinical pharmacokinetics: concepts and applications, 3rd edn. Lea & Febiger, Philadelphia, pp 119-136
5. Wolffenbuttel BHR, Graal MB (1996) New treatments for patients with type 2 diabetes mellitus. Postgrad Med J 72: 657- 662
6. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550-554
7. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-872
8. Bailey CJ, Turner RC (1996) Drug therapy: metformin. N Engl J Med 334: 574-579
9. Balfour JA, McTavish D (1993) Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46: 1025-1054
10. Anonymous (1998) Rezulin package insert. Parke-Davis
11. Patel J, Miller E, Hu J, Granett J (1997) BRL 49653 (a thiazolidinedione) improves glycemic control in NIDDM patients. Diabetes 46 [Suppl 1]: 150A
12. Miller E, Patel J, Reichek N, Granett J (1997) BRL 49653 (a thiazolidinedione) is well tolerated and has no effect on LV mass following 12 weeks treatment in NIDDM patients. Diabetes 46 [Suppl 1]: 96A
13. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P, for the Troglitazone Study Group (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701- 709
14. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T (1996) Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19: 151-156
15. Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level- time curve. J Pharmacokinet Biopharm 6: 539-547
16. Hauschke D, Steinijans VW, Diletti E (1990) A distribution- free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28: 72-78
17. Eldershaw TPD, Rattigan S, Cawthorne MA, Buckingham RE, Colquhoun EQ, Clark MG (1995) Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb. Horm Metab Res 27: 169-172
18. 2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812
19. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956
20. Freed MI, Miller A, Jorkasky DK, DiCicco RA (1998) Rosiglitazone pharmacokinetics are not affected by coadministration of ranitidine. Diabetes 48 [Suppl 1]: A353
21. Spencer CM, Markham A (1997) Troglitazone. Drugs 54: 89-101